Research progress on pharmacogenomics of anti-tuberculosis drugs

doi:10.3969/j.issn.1000-6621.2018.09.017

Abstract

Abstract:

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) infection, and the treatment of TB are mainly by chemical drugs. The researches on pharmacogenomics of anti-TB drugs focus on the application of pharmacogenomics in anti-TB treatment. Intensive researches in the field of genomics of anti-TB drugs will be helpful for paving the way of individual anti-TB treatment. This literature review study mainly introduced the current progress in the field of anti-TB pharmacogenomics research, including research methods for human genomics, pharmacogenomics and anti-TB drug metabolism, pharmacogenomics and anti-TB drug-induced liver damage, as well as pharmacogenomics and MTB resistance; the challenges of researches on anti-TB drug genomics were also explored.

Key words: Mycobacterium tuberculosis, Antibiotics, antitubercular, Genomics, Review literature as topic

Chen SHEN,A-dong SHEN. Research progress on pharmacogenomics of anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2018, 40(9): 993-998. doi: 10.3969/j.issn.1000-6621.2018.09.017

References 56

[1]	World Health Organization. Global tuberculosis report 2017. Geneva:World Health Organization, 2017.
[2]	Thorn CF, Klein TE, Altman RB . Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics, 2010,11(4):501-505. doi: 10.2217/pgs.10.15 URL pmid: 3098752
[3]	Devaleenal Daniel B, Ramachandran G, Swaminathan S . The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol, 2017,10(1):47-58. doi: 10.1080/17512433.2017.1246179 URL pmid: 27724114
[4]	Weiner M, Peloquin C, Burman W , et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother, 2010,54(10):4192-4200. doi: 10.1128/AAC.00353-10 URL
[5]	Chigutsa E, Visser ME, Swart EC , et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother, 2011,55(9):4122-4127. doi: 10.1128/AAC.01833-10 URL
[6]	WHO Guidelines Approved by the Guidelines Review Committee. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016. URL pmid: 27748093
[7]	Kita T, Tanigawara Y, Chikazawa S , et al. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull, 2001,24(5):544-549. doi: 10.1248/bpb.24.544 URL
[8]	Teixeira RL, Silva FP Jr, Silveira AR , et al. Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure. Mutat Res, 2010,683(1/2):43-49.
[9]	Singla N, Gupta D, Birbian N , et al. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb), 2014,94(3):293-298. doi: 10.1016/j.tube.2014.02.003 URL
[10]	Toure A, Cabral M, Niang A , et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Rep, 2016,3:826-831. doi: 10.1016/j.toxrep.2016.10.004 URL pmid: 28959610
[11]	Shen C, Qi H, Sun L , et al. A 3’UTR polymorphism of IL-6R is associated with Chinese pediatric tuberculosis. Biomed Res Int, 2014,2014:483759. doi: 10.1155/2014/483759 URL pmid: 3977562
[12]	Aminkeng F, Ross CJ, Rassekh SR , et al. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J, 2014,14(2):160-170. doi: 10.1038/tpj.2013.13 URL
[13]	Petros Z, Lee MM, Takahashi A , et al. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics, 2016,17(1):755. doi: 10.1186/s12864-016-3078-3 URL pmid: 3222227671213
[14]	Mokrousov I, Chernyaeva E, Vyazovaya A , et al. Next-Generation Sequencing of Mycobacterium tuberculosis. Emerg Infect Dis, 2016,22(6):1127-1129. doi: 10.3201/eid2206.152051 URL pmid: 27191040
[15]	Karczewski KJ, Daneshjou R, Altman RB . Chapter 7: pharmacogenomics. PLoS Comput Biol, 2012,8(12):e1002817. doi: 10.1371/journal.pcbi.1002817 URL
[16]	Golka K, Selinski S . NAT2 Genotype and Isoniazid Medication in Children. EBioMedicine, 2016,11:11-12. doi: 10.1016/j.ebiom.2016.08.040 URL pmid: 27591833
[17]	Parkin DP, Vandenplas S, Botha FJ , et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med, 1997,155(5):1717-1722. doi: 10.1164/ajrccm.155.5.9154882 URL pmid: 9154882
[18]	Kita T, Tanigawara Y, Chikazawa S , et al. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculosis patients. Biol Pharm Bull, 2001,24(5):544-549. doi: 10.1248/bpb.24.544 URL
[19]	Verhagen LM, Coenen M, López D ,et al. Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. Pharmacogenomics, 2014,15(3):285-296. doi: 10.2217/pgs.13.230 URL
[20]	Hemanth Kumar AK, Ramesh K, Kannan T , et al. NAT2 gene polymorphisms and plasma isoniazid concentrations in tuberculosis patients in south India. Indian J Med Res, 2017,145(1):118-123. doi: 10.4103/ijmr.IJMR_2013_15 URL
[21]	Jung JA, Kim TE, Lee H , et al. A proposal for an individuali-zed pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther, 2015,9:5433-5438.
[22]	Ji B, Truffot-Pernot C, Lacroix C , et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis, 1993,148(6 pt 1):1541-1546. doi: 10.1164/ajrccm/148.6_Pt_1.1541 URL
[23]	Jayaram R, Gaonkar S, Kaur P , et al. Pharmacokinetics and pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother, 2003,47(7):2118-2124. doi: 10.1128/AAC.47.7.2118-2124.2003 URL pmid: 161844
[24]	Jeremiah K, Denti P, Chigutsa E , et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother, 2014,58(6):3468-3474. doi: 10.1128/AAC.02307-13 URL
[25]	Ramesh K, Hemanth Kumar AK, Kannan T , et al. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a south Indian population. Int J Tuberc Lung Dis, 2016,20(9):1231-1235. doi: 10.5588/ijtld.15.1007 URL
[26]	Song SH, Chang HE, Jun SH , et al. Relationship between CES2 genetic variations and rifampicin metabolism. J Antimicrob Chemother, 2013,68(6):1281-1284. doi: 10.1093/jac/dkt036 URL pmid: 3222223471941
[27]	Fatiguso G, Allegra S, Calcagno A , et al. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. Int J Pharm, 2016,497(1/2):287-292. doi: 10.1016/j.ijpharm.2015.11.044 URL pmid: 26642947
[28]	Naidoo A, Ramsuran V, Chirehwa M , et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018,19(1):17-29. doi: 10.2217/pgs-2017-0144 URL
[29]	Weiner M, Burman W, Luo CC , et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother, 2007,51(8):2861-2866. doi: 10.1128/AAC.01621-06 URL pmid: 1932492
[30]	Weiner M, Gelfond J, Johnson-Pais TL , et al. Elevated plasma moxifloxacin concentrations and SLCO1B1 g.-11187G>A polymorphism in adults with pulmonary tuberculosis. Antimicrob Agents Chemother, 2018, 62(5). pii:e01802-17.
[31]	Zilber LA, Bajdakova, Gardasjan AN . The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ, 1963,29:457-481.
[32]	Roy PD, Majumder M, Roy B . Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics, 2008,9(3):311-321. doi: 10.2217/14622416.9.3.311 URL pmid: 3222218303967
[33]	Lee SW, Chung LS, Huang HH , et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis, 2010,14(5):622-626.
[34]	Cho HJ, Koh WJ, Ryu YJ , et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis, 2007,87(6):551-556. doi: 10.1016/j.tube.2007.05.012 URL
[35]	Stettner M, Steinberger D, Hartmann CJ , et al. Isoniazid-induced polyneuropathy in a tuberculosis patient implication for individual risk stratification with genotyping? Brain Behav, 2015,5:e00326.
[36]	Azuma J, Ohno M, Kubota R , et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmaco-genetics-based therapy. Eur J Clin Pharmacol, 2013,69(5):1091-1101. doi: 10.1007/s00228-012-1429-9 URL
[37]	Kubota R, Ohno M, Hasunuma T , et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyl transferase 2. Eur J Clin Pharmacol, 2007,63(10):927-933. doi: 10.1007/s00228-007-0333-1 URL
[38]	Wang PY, Xie SY, Hao Q , et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis, 2012,16(5):589-595. doi: 10.5588/ijtld.11.0377 URL
[39]	张金玲, 朱学彬, 李世明 , 等. SLCO1B1/ABCB1基因多态性与抗结核药物性肝损伤的相关性分析. 中华疾病控制杂志, 2013,17(6):469-472.
[40]	向阳, 孙凤, 詹思延 . 抗结核药物致肝损害与CYP2E1基因多态性. 中国公共卫生, 2011,21(7):910-913.
[41]	武鑫, 刘春亮, 薛刚 , 等. 中国人细胞色素P450 2E1基因多态性与抗结核药物性肝损害关系的Meta分析. 中华临床医师杂志(电子版), 2017,11(7):1147-1152. doi: 10.3877/cma.j.issn.1674-0785.2017.07.019 URL
[42]	Li C, Long J, Hu X , et al. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur J Clin Microbiol Infect Dis, 2013,32(7):859-868. doi: 10.1007/s10096-013-1831-y URL
[43]	朱冬林, 席云, 吴雪琼 . GSTM1和GSTT1基因多态性与抗结核药物性肝损害的关系. 中国抗生素杂志, 2011,36(11):864-866.
[44]	Liu F, Jiao AX, Wu XR , et al. Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatoto-xicity in Chinese pediatric patients, PLoS One, 2014,9(12):e115410. doi: 10.1371/journal.pone.0115410 URL
[45]	祖丽娅·沙塔尔, 顾佳怡, 马晨晨 , 等. GSTM1、GSTT1基因多态性与抗结核药物所致肝损害的相关性分析. 新疆医科大学学报, 2017,40(6):762-766.
[46]	Zhang W, He YJ, Gan Z , et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol, 2007,34(12):1240-1244. doi: 10.1111/cep.2007.34.issue-12 URL
[47]	Li LM, Chen L, Deng GH , et al. SLCO1B1*15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep, 2012,6(1):75-82. doi: 10.3892/mmr.2012.900 URL pmid: 22562052
[48]	马艳, 尹韶华, 杜建 , 等. 383例耐药肺结核患者的相关危险因素分析, 结核病与肺部健康杂志, 2018,7(2):128-134. doi: 10.3969/j.issn.2095-3755.2016.02.015 URL
[49]	Pasipanodya JG, Srivastava S, Gumbo T . Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis, 2012,55(2):169-177. doi: 10.1093/cid/cis353 URL
[50]	Pontual Y, Pacheco VSS, Monteiro SP , et al. ABCB1 gene polymorphism associated with clinical factors can predict drug-resistant tuberculosis. Clin Sci (Lond), 2017,131(15):1831-1840. doi: 10.1042/CS20170277 URL
[51]	Rodríguez-Castillo JA, Arce-Mendoza AY, Quintanilla-Siller A , et al. Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis. Tuberculosis (Edinb), 2015,95(5):532-537. doi: 10.1016/j.tube.2015.04.004 URL
[52]	Mushiroda T, Yanai H, Yoshiyama T , et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Hum Genome Var, 2016,3:16014. doi: 10.1038/hgv.2016.14 URL
[53]	Karczewski KJ, Daneshjou R, Altman RB . Chapter 7: pharmacogenomics. PLoS Comput Biol, 2012,8(12):e1002817. doi: 10.1371/journal.pcbi.1002817 URL
[54]	Wasserman S, Meintjes G, Maartens G . Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther, 2016,14(10):901-915. doi: 10.1080/14787210.2016.1225498 URL
[55]	Bardien S, Human H, Harris T , et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet, 2009,10:2.
[56]	邓体瑛 . 抗结核药物研究进展. 中国新药与临床杂志, 2017,36(11):629-634.